Cetuximab

CLINICAL USE

Monoclonal antibody:

Treatment of EGFR-expressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecan-including cytotoxic therapy

DOSE IN NORMAL RENAL FUNCTION

Initial dose 400 mg/m2 then 250 mg/m2 weekly

PHARMACOKINETICS

Molecular weight :152 000

%Protein binding :No data

%Excreted unchanged in urine : minimal

Volume of distribution (L/kg) :1.5–6.2 L/m2

half-life – normal/ESRD (hrs) :70–100/unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function. Use with caution

10 to 20 : Dose as in normal renal function. Use with caution

<10 : Dose as in normal renal function. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in GFR <10 mL/min

HD :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux :Not dialysed. Dose as in GFR <10 mL/min

CAV/VVHD :Not dialysed. Dose as in GFR=10–20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

IV infusion

Rate of Administration

1st dose: 120 minutes Further doses: 60 minutes Maximum infusion rate must not exceed 5 mL/min

Comments

Administer via a 0.2 micrometer in-line filterThe filter may clog and need to be replaced during the infusion

OTHER INFORMATION

Delayed hypersensitivity reactions may occur and patients should be warned to contact their doctor if this occurs

Premedication with an antihistamine is recommended

2% of patients receiving cetuximab developed renal failure

Give irinotecan at least 1 hour after the end of cetuximab infusion.

Tags: post-by-auto-php